Clinical Trials Browser

Interventional × cabozantinib × Sarcoma × Clear all

NCT05836571 2026-04-21

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Phase 2 Active not recruiting

Sarcoma, Histiocytoma, Malignant Fibrous

NCT05019703 2026-04-17

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Phase 2 Recruiting

Osteosarcoma

NCT05691478 2026-04-15

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Phase 2/3 Recruiting

Osteosarcoma

NCT02243605 2026-04-13

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Phase 2 Active not recruiting

90 enrolled 15 charts

Sarcoma, Ewing, Osteosarcoma

NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase 2 Active not recruiting

109 enrolled 24 charts

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT06341712 2026-03-31

CabOSTar

Phase 2 Terminated

Osteosarcoma

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing

NCT04200443 2026-01-05

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Phase 2 Active not recruiting

Leiomyosarcoma, Sarcoma

NCT05039281 2025-12-19

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Phase 1/2 Recruiting

Glioblastoma, Gliosarcoma

NCT06156410 2025-11-14

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Phase 1 Recruiting

Recurrence, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT04551430 2025-11-12

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Phase 2 Active not recruiting

Sarcoma

NCT05182164 2025-10-07

PEMBROCABOSARC

Phase 2 Recruiting

Sarcoma, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Phase 2 Recruiting

CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT03367741 2025-07-28

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT01755195 2024-01-03

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Phase 2 Completed

55 enrolled 16 charts

Sarcoma

NCT04661852 2023-02-15

Cabozantinib With Topotecan-Cyclophosphamide

Phase 1 Completed

Sarcoma, Ewing, Osteosarcoma

NCT02216578 2021-07-15

Ph II CABOGIST in GIST

Phase 2 Completed

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors